Product Image

Contributor Information

  • Institute Versiti Blood Research Institute

Tool Details

  • Tool name: Anti-vWFACTOR AGII pp [MBC 239.3]
  • Alternate names: vWFpp
  • Tool type: Antibodies
  • Tool sub-type: Primary Antibody
  • Class: Monoclonal
  • Conjugate: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Molecular weight of the target: 75 kDa
  • Application: ELISA
  • Description: Von Willebrand factor (vWF) is a multimeric plasma glycoprotein that functions in hemostasis as the initiator of platelet adhesion at the site of vascular injury and as the carrier of the anti-hemophilic factor, factor VIII (FVIII). Hereditary or acquired defects of VWF lead to von Willebrand disease (vWD), a bleeding diathesis of the skin and mucous membranes, causing nosebleeds, menorrhagia, and gastrointestinal bleeding.
  • Immunogen: vWF Pro-peptide formerly named Human-AGII
  • Research area: Immunology
  • Myeloma used: P3X63Ag8.653

  • For Research Use Only

Target Details

  • Target: von Willebrand Factor Antigen II (vWf:AgII)
  • Target molecular weight: 75 kDa
  • Target background: Von Willebrand factor (vWF) is a multimeric plasma glycoprotein that functions in hemostasis as the initiator of platelet adhesion at the site of vascular injury and as the carrier of the anti-hemophilic factor, factor VIII (FVIII). Hereditary or acquired defects of VWF lead to von Willebrand disease (vWD), a bleeding diathesis of the skin and mucous membranes, causing nosebleeds, menorrhagia, and gastrointestinal bleeding.

Application Details

  • Application: ELISA

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15°C to -25°C
  • Shipping conditions: Shipping at 4°C

Documentation

Related Tools

Product Image

Anti-Aspergillus fumigatus, [16C4]

#153457
Product Image

Anti-AP2b [AP2bbeta 1F3/8]

#151274
Product Image

Anti-CUGBP2/ETR-3 [1H2-1F12]

#158408

References

  • •  Haberichter et al. 2006. Blood. 108(10):3344-51. PMID: 16835381.